Dante Labs has announced a $41m investment in the UK to run a global surveillance programme of the new variants of the SARS-CoV-2 virus, starting with a capacity of 50,000 RNA samples per week.
In 2020, Dante Labs used its Immensa Genome Platform to support COVID-19 testing at scale.
The company built Immensa as a smart software platform that uses machine learning to advance the interpretation of the human genome with every analysis.
“The SARS-CoV-2 RNA may be simpler to analyse than the human genome. Yet both require massive investments in software and people,” says Dante Labs CEO Andrea Riposati, “Today the UK is the best country to invest in, a global leader in genomics and a beacon of hope for the future of humanity.”
